Novartis announced the appointment of a new chief legal and compliance officer on Monday morning, following the departure of Klaus Moosmayer, who currently serves as chief ethics, risk and compliance ...
Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 evidence ...
--Up 18.04% from 52 weeks ago (Oct. 31, 2023), when it closed at $93.58 --Down 8.62% from its 52-week closing high of $120.89 on Aug. 30, 2024 --Up 19.33% from its 52-week closing low of $92.57 on ...
ZURICH, Feb 17 (Reuters) - Novartis (NOVN.S), opens new tab has entered into a grant agreement with the Bill & Melinda Gates Foundation to fund the development of accessible single use gene therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback